2026 Global: Car T-Cell Therapy Market-Competitive Review (2032) report
Description
The 2026 Global: Car T-Cell Therapy Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for car t-cell therapy market by geography and historical trend. The scope of the report extends to sizing of the car t-cell therapy market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The CAR T-cell therapy market is dominated by ten major companies driving innovation in cancer and autoimmune treatments through advanced T-cell engineering. Kite Pharma (Gilead) leads with Yescarta, the second FDA-approved CAR T for non-Hodgkin lymphoma, expanding manufacturing in Maryland and partnering for in vivo therapies worth up to $1.64 billion with Pregene Biopharma. Bristol Myers Squibb (BMS), via Celgene's $9 billion acquisition of Juno and $74 billion buyout, markets Breyanzi and Abecma, generating $747 million and $406 million in sales, while investing $1.5 billion in Orbital Therapeutics for RNA-reprogrammed immune cells. Johnson & Johnson (J&J), partnering with Legend Biotech, commercializes Carvykti for multiple myeloma with $963 million in sales and 89% undetectable cancer rates in Phase III trials, advancing JNJ-4496 with 100% response in lymphoma. Novartis pioneers with Kymriah, holding multiple approvals, and remains a pipeline leader alongside Cartesian Therapeutics and Poseida. Autolus Therapeutics boasts a top-five pipeline with four hematological and one solid tumor candidate, building U.S. facilities in Maryland and progressing despite BioNTech's opt-out.
These companies expand beyond oncology into autoimmune diseases and solid tumors, leveraging strategic acquisitions and manufacturing scale. Legend Biotech co-develops Carvykti, solidifying J&J's position, while Kyverna Therapeutics advances KYV-101 targeting CD19 for autoimmunity, nearing FDA approval with $150 million funding and deep B-cell depletion in trials. Carsgen Therapeutics secured China approval for zevor-cel in relapsed multiple myeloma and partnered with Huadong Medicine for $29.7 million upfront plus $152.4 million milestones, building U.S.-China platforms for hematologic and solid tumors. JW Therapeutics and Arcellx focus on integrated pipelines; JW emphasizes global commercialization, Arcellx raised $27 million for novel CAR T paradigms in cancer and broad diseases from Maryland's Germantown hub. Cartesian Therapeutics pioneers mRNA-engineered therapies in clinical trials for oncology, respiratory, and autoimmune disorders at its Gaithersburg facility, positioning as a leader in customizable cell delivery.
Market leaders invest heavily in next-generation platforms amid over 90 therapies in trials worldwide. Amgen collaborates with Kite on eACT™ for cancer targets, while Atara Biotherapeutics develops off-the-shelf allogeneic T cells from healthy donors, constructing a $55 million CAR T facility in California for rapid inventory delivery. Expansion into point-of-care like Galapagos' CellPoint acquisition and in vivo shifts by Kite and BMS signal maturation, with Maryland hubs like Autolus and Kite creating jobs and fueling pipelines despite 2025 closures elsewhere. These firms control approved products, robust trials, and manufacturing, capturing the market's meteoric rise through immuno-oncology dominance and autoimmune frontiers. (452 words)
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for car t-cell therapy market by geography and historical trend. The scope of the report extends to sizing of the car t-cell therapy market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The CAR T-cell therapy market is dominated by ten major companies driving innovation in cancer and autoimmune treatments through advanced T-cell engineering. Kite Pharma (Gilead) leads with Yescarta, the second FDA-approved CAR T for non-Hodgkin lymphoma, expanding manufacturing in Maryland and partnering for in vivo therapies worth up to $1.64 billion with Pregene Biopharma. Bristol Myers Squibb (BMS), via Celgene's $9 billion acquisition of Juno and $74 billion buyout, markets Breyanzi and Abecma, generating $747 million and $406 million in sales, while investing $1.5 billion in Orbital Therapeutics for RNA-reprogrammed immune cells. Johnson & Johnson (J&J), partnering with Legend Biotech, commercializes Carvykti for multiple myeloma with $963 million in sales and 89% undetectable cancer rates in Phase III trials, advancing JNJ-4496 with 100% response in lymphoma. Novartis pioneers with Kymriah, holding multiple approvals, and remains a pipeline leader alongside Cartesian Therapeutics and Poseida. Autolus Therapeutics boasts a top-five pipeline with four hematological and one solid tumor candidate, building U.S. facilities in Maryland and progressing despite BioNTech's opt-out.
These companies expand beyond oncology into autoimmune diseases and solid tumors, leveraging strategic acquisitions and manufacturing scale. Legend Biotech co-develops Carvykti, solidifying J&J's position, while Kyverna Therapeutics advances KYV-101 targeting CD19 for autoimmunity, nearing FDA approval with $150 million funding and deep B-cell depletion in trials. Carsgen Therapeutics secured China approval for zevor-cel in relapsed multiple myeloma and partnered with Huadong Medicine for $29.7 million upfront plus $152.4 million milestones, building U.S.-China platforms for hematologic and solid tumors. JW Therapeutics and Arcellx focus on integrated pipelines; JW emphasizes global commercialization, Arcellx raised $27 million for novel CAR T paradigms in cancer and broad diseases from Maryland's Germantown hub. Cartesian Therapeutics pioneers mRNA-engineered therapies in clinical trials for oncology, respiratory, and autoimmune disorders at its Gaithersburg facility, positioning as a leader in customizable cell delivery.
Market leaders invest heavily in next-generation platforms amid over 90 therapies in trials worldwide. Amgen collaborates with Kite on eACT™ for cancer targets, while Atara Biotherapeutics develops off-the-shelf allogeneic T cells from healthy donors, constructing a $55 million CAR T facility in California for rapid inventory delivery. Expansion into point-of-care like Galapagos' CellPoint acquisition and in vivo shifts by Kite and BMS signal maturation, with Maryland hubs like Autolus and Kite creating jobs and fueling pipelines despite 2025 closures elsewhere. These firms control approved products, robust trials, and manufacturing, capturing the market's meteoric rise through immuno-oncology dominance and autoimmune frontiers. (452 words)
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
